Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment

Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment PurposeThis review provides an update on the current clinical, epidemiological and pathophysiological evidence alongside the diagnostic, prevention and treatment approach to chemotherapy-induced peripheral neuropathy (CIPN).FindingsThe incidence of cancer and long-term survival after treatment is increasing. CIPN affects sensory, motor and autonomic nerves and is one of the most common adverse events caused by chemotherapeutic agents, which in severe cases leads to dose reduction or treatment cessation, with increased mortality. The primary classes of chemotherapeutic agents associated with CIPN are platinum-based drugs, taxanes, vinca alkaloids, bortezomib and thalidomide. Platinum agents are the most neurotoxic, with oxaliplatin causing the highest prevalence of CIPN. CIPN can progress from acute to chronic, may deteriorate even after treatment cessation (a phenomenon known as coasting) or only partially attenuate. Different chemotherapeutic agents share both similarities and key differences in pathophysiology and clinical presentation. The diagnosis of CIPN relies heavily on identifying symptoms, with limited objective diagnostic approaches targeting the class of affected nerve fibres. Studies have consistently failed to identify at-risk cohorts, and there are no proven strategies or interventions to prevent or limit the development of CIPN. Furthermore, multiple treatments developed to relieve symptoms and to modify the underlying disease in CIPN have failed.ImplicationsThe increasing prevalence of CIPN demands an objective approach to identify at-risk patients in order to prevent or limit progression and effectively alleviate the symptoms associated with CIPN. An evidence base for novel targets and both pharmacological and non-pharmacological treatments is beginning to emerge and has been recognised recently in publications by the American Society of Clinical Oncology and analgesic trial design expert groups such as ACTTION. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment

Download PDF
66 pages

Loading next page...
 
/lp/springer-journals/chemotherapy-induced-peripheral-neuropathy-epidemiology-0VBL1IvYwR
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-021-00168-y
Publisher site
See Article on Publisher Site

Abstract

PurposeThis review provides an update on the current clinical, epidemiological and pathophysiological evidence alongside the diagnostic, prevention and treatment approach to chemotherapy-induced peripheral neuropathy (CIPN).FindingsThe incidence of cancer and long-term survival after treatment is increasing. CIPN affects sensory, motor and autonomic nerves and is one of the most common adverse events caused by chemotherapeutic agents, which in severe cases leads to dose reduction or treatment cessation, with increased mortality. The primary classes of chemotherapeutic agents associated with CIPN are platinum-based drugs, taxanes, vinca alkaloids, bortezomib and thalidomide. Platinum agents are the most neurotoxic, with oxaliplatin causing the highest prevalence of CIPN. CIPN can progress from acute to chronic, may deteriorate even after treatment cessation (a phenomenon known as coasting) or only partially attenuate. Different chemotherapeutic agents share both similarities and key differences in pathophysiology and clinical presentation. The diagnosis of CIPN relies heavily on identifying symptoms, with limited objective diagnostic approaches targeting the class of affected nerve fibres. Studies have consistently failed to identify at-risk cohorts, and there are no proven strategies or interventions to prevent or limit the development of CIPN. Furthermore, multiple treatments developed to relieve symptoms and to modify the underlying disease in CIPN have failed.ImplicationsThe increasing prevalence of CIPN demands an objective approach to identify at-risk patients in order to prevent or limit progression and effectively alleviate the symptoms associated with CIPN. An evidence base for novel targets and both pharmacological and non-pharmacological treatments is beginning to emerge and has been recognised recently in publications by the American Society of Clinical Oncology and analgesic trial design expert groups such as ACTTION.

Journal

Oncology and Therapy – Springer Journals

Published: Dec 1, 2021

Keywords: Chemotherapy; Epidemiology; Mechanism of action; Neuropathy; Neurotoxicity; Oxaliplatin; Paclitaxel; Pain; Peripheral neuropathy; Prevalence

References

  • Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, F; Ferlay, J; Soerjomataram, I; Siegel, RL; Torre, LA; Jemal, A
  • Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study
    Arnold, M; Rutherford, MJ; Bardot, A; Ferlay, J; Andersson, TML; Myklebust, TÅ
  • Cancer statistics, 2019
    Siegel, RL; Miller, KD; Jemal, A
  • Invasive cancer incidence and survival-United States, 2012
    Henley, SJ; Singh, SD; King, J; Wilson, RJ; O'Neil, ME; Ryerson, AB
  • Chemotherapy-induced peripheral neurotoxicity (CIPN): an update
    Argyriou, AA; Bruna, J; Marmiroli, P; Cavaletti, G
  • Chemotherapy-induced peripheral neurotoxicity. Nature reviews
    Cavaletti, G; Marmiroli, P
  • Chemotherapy-induced peripheral neurotoxicity (CIPN): the dilemma of proper assessment
    Cavaletti, G; Grp, CIPS
  • Chemotherapy-induced peripheral neuropathy: where are we now?
    Colvin, LA
  • Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
    Seretny, M; Currie, GL; Sena, ES; Ramnarine, S; Grant, R; MacLeod, MR
  • CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    Trotti, A; Colevas, AD; Setser, A; Rusch, V; Jaques, D; Budach, V
  • In search of a gold standard patient-reported outcome measure for use in chemotherapy-induced peripheral neuropathy clinical trials
    Smith, EML; Knoerl, R; Yang, JJ; Kanzawa-Lee, G; Lee, D; Bridges, CM
  • The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums
    Smith, EML; Cohen, JA; Pett, MA; Beck, SL
  • Chemotherapy-induced peripheral neuropathy: prevention and treatment
    Pachman, DR; Barton, DL; Watson, JC; Loprinzi, CL
  • Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
    Molassiotis, A; Cheng, HL; Lopez, V; Au, JSK; Chan, A; Bandla, A
  • Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the treatment-induced neuropathy assessment scale
    Mendoza, TR; Wang, XS; Williams, LA; Shi, Q; Vichaya, EG; Dougherty, PM
  • Oxaliplatin scale and National Cancer Institute-common toxicity criteria in the assessment of chemotherapy-induced peripheral neuropathy
    Kautio, AL; Saarto, T; Haanpää, M; Leminen, A; Kalso, E; Kautiainen, H
  • The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale
    Cavaletti, G; Frigeni, B; Lanzani, F; Piatti, M; Rota, S; Briani, C
  • Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin
    Alberti, P; Rossi, E; Cornblath, DR; Merkies, ISJ; Postma, TJ; Frigeni, B
  • Chemotherapy-induced peripheral neurotoxicity—outcome measures: the issue
    Alberti, P
  • Chemotherapy-induced peripheral neuropathy: a challenge for clinicians
    Abdi, S; Dougherty, PM
  • Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial
    Park, SB; Kwok, JB; Asher, R; Lee, CK; Beale, P; Selle, F
  • Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy
    Yeo, F; Ng, CC; Loh, KWJ; Molassiotis, A; Cheng, HL; Au, JSK
  • Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance)
    Pachman, DR; Qin, R; Seisler, DK; Smith, EML; Beutler, AS; Ta, LE
  • Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III Trial N08CB (Alliance)
    Pachman, DR; Qin, R; Seisler, DK; Smith, EM; Beutler, AS; Ta, LE
  • Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)
    Pachman, DR; Qin, R; Seisler, D; Smith, EM; Kaggal, S; Novotny, P
  • Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials
    Le-Rademacher, J; Kanwar, R; Seisler, D; Pachman, DR; Qin, R; Abyzov, A
  • Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: a qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale
    Kaiser, K; Lyleroehr, M; Shaunfield, S; Lacson, L; Corona, M; Kircher, S
  • Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy
    Soveri, LM; Lamminmaki, A; Hanninen, UA; Karhunen, M; Bono, P; Osterlund, P
  • Multifocal neuropathy in vinorelbine treatment for breast cancer (P6.186)
    Grisold, A; Ackerl, M; Surböck, B; Giometto, B; Grisold, W
  • Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment
    Tamburin, S; Park, SB; Alberti, P; Demichelis, C; Schenone, A; Argyriou, AA
  • Managing treatment-related peripheral neuropathy in patients with multiple myeloma
    Grammatico, S; Cesini, L; Petrucci, MT
  • Bortezomib-associated demyelinating neuropathy—clinical and pathologic features
    Thawani, SP; Tanji, K; De Sousa, EA; Weimer, LH; Brannagan, TH
  • Cancer treatment and survivorship statistics
    Miller, KD; Siegel, RL; Lin, CC; Mariotto, AB; Kramer, JL; Rowland, JH
  • Capecitabine and oxaliplatin for advanced esophagogastric cancer
    Cunningham, D; Starling, N; Rao, S; Iveson, T; Nicolson, M; Coxon, F
  • Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial
    Hall, PS; Swinson, D; Waters, JS; Wadsley, J; Falk, S; Roy, R
  • Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Al-Batran, S-E; Homann, N; Pauligk, C; Goetze, TO; Meiler, J; Kasper, S
  • Mechanisms of chemotherapy-induced peripheral neuropathy
    Zajączkowska, R; Kocot-Kępska, M; Leppert, W; Wrzosek, A; Mika, J; Wordliczek, J
  • Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
    Hana, S; Irina, V
  • Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies
    Kroigard, T; Schroder, HD; Qvortrup, C; Eckhoff, L; Pfeiffer, P; Gaist, D
  • The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review
    Gebremedhn, EG; Shortland, PJ; Mahns, DA
  • Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility
    Park, SB; Lin, CSY; Krishnan, AV; Goldstein, D; Friedlander, ML; Kiernan, MC
  • Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy
    Lehky, TJ; Leonard, GD; Wilson, RH; Grem, JL; Floeter, MK
  • Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
    Land, SR; Kopec, JA; Cecchini, RS; Ganz, PA; Wieand, HS; Colangelo, LH
  • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A; Figer, A; Seymour, M; Homerin, M; Hmissi, A; Cassidy, J
  • Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study
    Briani, C; Argyriou, AA; Izquierdo, C; Velasco, R; Campagnolo, M; Alberti, P
  • Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity
    Branca, JJV; Morucci, G; Paternostro, F; Gulisano, M; Pacini, A; Maresca, M
  • Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy
    Fujita, S; Hirota, T; Sakiyama, R; Baba, M; Ieiri, I
  • Chemotherapy-induced neuropathies-a growing problem for patients and health care providers
    Banach, M; Juranek, JK; Zygulska, AL
  • Role of MAPKs in platinum-induced neuronal apoptosis
    Scuteri, A; Galimberti, A; Maggioni, D; Ravasi, M; Pasini, S; Nicolini, G
  • Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy
    Melli, G; Taiana, M; Camozzi, F; Triolo, D; Podini, P; Quattrini, A
  • Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons
    Podratz, JL; Knight, AM; Ta, LE; Staff, NP; Gass, JM; Genelin, K
  • Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction
    Flatters, SJL; Bennett, GJ
  • Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy
    Zheng, H; Xiao, WH; Bennett, GJ
  • Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding
    Ta, LE; Espeset, L; Podratz, J; Windebank, AJ
  • Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: Could it correlate with in vivo neuropathy?
    Di Cesare, ML; Zanardelli, M; Failli, P; Ghelardini, C
  • Evaluation of multi-neuroprotective effects of erythropoietin using cisplatin induced peripheral neurotoxicity model
    Sharawy, N; Rashed, L; Youakim, MF
  • Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy
    Joseph, EK; Chen, X; Bogen, O; Levine, JD
  • Metals, toxicity and oxidative stress
    Valko, M; Morris, H; Cronin, MT
  • Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin
    Di Cesare, ML; Zanardelli, M; Failli, P; Ghelardini, C
  • Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain
    Shim, HS; Bae, C; Wang, J; Lee, KH; Hankerd, KM; Kim, HK
  • Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: possible aid in chemotherapy induced neuropathy
    Di Cesare, ML; Zanardelli, M; Landini, I; Pacini, A; Ghelardini, C; Mini, E
  • Down-regulation of Kv43 channels and a-type K+ currents in V2 trigeminal ganglion neurons of rats following oxaliplatin treatment
    Viatchenko-Karpinski, V; Ling, J; Gu, JG
  • Acute changes in nerve excitability following oxaliplatin treatment in mice
    Makker, PGS; White, D; Lees, JG; Parmar, J; Goldstein, D; Park, SB
  • Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity
    Alberti, P; Canta, A; Chiorazzi, A; Fumagalli, G; Meregalli, C; Monza, L
  • Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation
    Kono, T; Satomi, M; Suno, M; Kimura, N; Yamazaki, H; Furukawa, H
  • Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors
    Descoeur, J; Pereira, V; Pizzoccaro, A; Francois, A; Ling, B; Maffre, V
  • Oxaliplatin, an anticancer agent that affects both Na^+ and K^+ channels in frog peripheral myelinated axons
    Benoit, E; Brienza, S; Dubois, JM
  • Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms
    Wahlman, C; Doyle, TM; Little, JW; Luongo, L; Janes, K; Chen, Z
  • Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat
    Robinson, CR; Zhang, H; Dougherty, PM
  • Triggering receptor expressed on myeloid cells 2 (TREM2) dependent microglial activation promotes cisplatin-induced peripheral neuropathy in mice
    Hu, LY; Zhou, Y; Cui, WQ; Hu, XM; Du, LX; Mi, WL
  • Paclitaxel in cancer therapy
    Mekhail, TM; Markman, M
  • Update on taxane development: new analogs and new formulations
    Yared, JA; Tkaczuk, KH
  • Chemotherapy-induced peripheral neuropathy: current status and progress
    Brewer, JR; Morrison, G; Dolan, ME; Fleming, GF
  • Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management
    Swain, SM; Arezzo, JC
  • Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients
    Dougherty, PM; Cata, JP; Cordella, JV; Burton, A; Weng, HR
  • Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere)
    Hilkens, PH; Verweij, J; Vecht, CJ; Stoter, G; van den Bent, MJ
  • Long-term peripheral neuropathy symptoms in breast cancer survivors
    Mustafa Ali, M; Moeller, M; Rybicki, L; Moore, HCF
  • Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30
    Bandos, H; Melnikow, J; Rivera, DR; Swain, SM; Sturtz, K; Fehrenbacher, L
  • Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes
    de la Morena, BP; Conesa, M; González-Billalabeitia, E; Urrego, E; García-Garre, E; García-Martínez, E
  • What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer
    Bridges, CM; Smith, EM
  • Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial
    Bonomi, P; Kim, K; Fairclough, D; Cella, D; Kugler, J; Rowinsky, E
  • Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial
    Shimozuma, K; Ohashi, Y; Takeuchi, A; Aranishi, T; Morita, S; Kuroi, K
  • Activating transcription factor 3, a useful marker for regenerative response after nerve root injury
    Lindå, H; Sköld, MK; Ochsmann, T
  • Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore
    Kidd, JF; Pilkington, MF; Schell, MJ; Fogarty, KE; Skepper, JN; Taylor, CW
  • HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy
    Krukowski, K; Ma, J; Laumet, GO; Gutti, T; Heijnen, CJ; Kavelaars, A
  • Chemotherapy-induced neuropathy
    Windebank, AJ; Grisold, W
  • MitoVitE, a mitochondria-targeted antioxidant, limits paclitaxel-induced oxidative stress and mitochondrial damage in vitro, and paclitaxel-induced mechanical hypersensitivity in a rat pain model
    McCormick, B; Lowes, DA; Colvin, L; Torsney, C; Galley, HF
  • Dorsal root ganglion neurons become hyperexcitable and increase expression of voltage-gated T-type calcium channels (Cav3.2) in paclitaxel-induced peripheral neuropathy
    Li, Y; Tatsui, CE; Rhines, LD; North, RY; Harrison, DS; Cassidy, RM
  • Terminal arbor degeneration—a novel lesion produced by the antineoplastic agent paclitaxel
    Bennett, GJ; Liu, GK; Xiao, WH; Jin, HW; Siau, C
  • DRG voltage-gated sodium channel 1.7 is upregulated in paclitaxel-induced neuropathy in rats and in humans with neuropathic pain
    Li, Y; North, RY; Rhines, LD; Tatsui, CE; Rao, G; Edwards, DD
  • Expression and role of voltage-gated sodium channels in human dorsal root ganglion neurons with special focus on Nav1.7, species differences, and regulation by paclitaxel
    Chang, W; Berta, T; Kim, YH; Ji, RR; Lee, S; Lee, SY
  • Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy
    Li, Y; Zhang, H; Zhang, H; Kosturakis, AK; Jawad, AB; Dougherty, PM
  • MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy
    Li, Y; Zhang, H; Kosturakis, AK; Cassidy, RM; Zhang, H; Kennamer-Chapman, RM
  • The cancer chemotherapeutic paclitaxel increases human and rodent sensory neuron responses to TRPV1 by activation of TLR4
    Li, Y; Adamek, P; Zhang, H; Tatsui, CE; Rhines, LD; Mrozkova, P
  • Cytokines IL-1b, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFa in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel
    Penson, RT; Kronish, K; Duan, Z; Feller, A; Stark, P; Cook, SE
  • Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells
    Siau, C; Xiao, W; Bennett, GJ
  • CD8+ T cells and endogenous IL-10 are required for resolution of chemotherapy-induced neuropathic pain
    Krukowski, K; Eijkelkamp, N; Laumet, G; Hack, CE; Yan, L; Dougherty, PM
  • Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats
    Ledeboer, A; Jekich, BM; Sloane, EM; Mahoney, JH; Langer, SJ; Milligan, ED
  • An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat
    Peters, CM; Jimenez-Andrade, JM; Kuskowski, MA; Ghilardi, JR; Mantyh, PW
  • Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: from pathogenesis to treatment
    Islam, B; Lustberg, M; Staff, NP; Kolb, N; Alberti, P; Argyriou, AA
  • Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening
    Verstappen, CCP; Koeppen, S; Heimans, JJ; Huijgens, PC; Scheulen, ME; Strumberg, D
  • Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
    Madsen, ML; Due, H; Ejskjær, N; Jensen, P; Madsen, J; Dybkær, K
  • Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis
    Kanbayashi, Y; Hosokawa, T; Okamoto, K; Konishi, H; Otsuji, E; Yoshikawa, T
  • Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study
    Chauvenet, AR; Shashi, V; Selsky, C; Morgan, E; Kurtzberg, J; Bell, B
  • Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St Jude Lifetime Cohort Study
    Ness, KK; Jones, KE; Smith, WA; Spunt, SL; Wilson, CL; Armstrong, GT
  • Efficacy and safety of pertuzumab and trastuzumab administered in a single infusion bag, followed by vinorelbine: VELVET Cohort 2 final results
    Andersson, M; López-Vega, JM; Petit, T; Zamagni, C; Easton, V; Kamber, J
  • Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas
    Haim, N; Epelbaum, R; Ben-Shahar, M; Yarnitsky, D; Simri, W; Robinson, E
  • Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: clinical, neurophysiological, functional, and patient-reported outcomes
    Kandula, T; Farrar, MA; Cohn, RJ; Mizrahi, D; Carey, K; Johnston, K
  • Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat
    Topp, KS; Tanner, KD; Levine, JD
  • Drugs that target dynamic microtubules: a new molecular perspective
    Stanton, RA; Gernert, KM; Nettles, JH; Aneja, R
  • Update on chemotherapy-induced peripheral neuropathy
    Cioroiu, C; Weimer, LH
  • Mitochondrial electron transport in models of neuropathic and inflammatory pain
    Joseph, EK; Levine, JD
  • Axon self-destruction: new links among SARM1, MAPKs, and NAD+ metabolism
    Gerdts, J; Summers, DW; Milbrandt, J; DiAntonio, A
  • Levo-corydalmine attenuates vincristine-induced neuropathic pain in mice by upregulating the Nrf2/HO-1/CO pathway to inhibit connexin 43 expression
    Zhou, L; Ao, L; Yan, Y; Li, C; Li, W; Ye, A
  • The protective effect of modafinil on vincristine-induced peripheral neuropathy in rats: a possible role for TRPA1 receptors
    Amirkhanloo, F; Karimi, G; Yousefi-Manesh, H; Abdollahi, A; Roohbakhsh, A; Dehpour, AR
  • Investigation of key genes and pathways in inhibition of oxycodone on vincristine-induced microglia activation by using bioinformatics analysis
    Liu, W; Ye, J; Yan, H
  • Risk factors and outcomes of thalidomide-induced peripheral neuropathy in a pediatric inflammatory bowel disease cohort
    Bramuzzo, M; Stocco, G; Montico, M; Arrigo, S; Calvi, A; Lanteri, P
  • Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus
    Briani, C; Zara, G; Rondinone, R; Iaccarino, L; Ruggero, S; Toffanin, E
  • Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients
    Bastuji-Garin, S; Ochonisky, S; Bouche, P; Gherardi, RK; Duguet, C; Djerradine, Z
  • Thalidomide and sensory neurotoxicity: a neurophysiological study
    Zara, G; Ermani, M; Rondinone, R; Arienti, S; Doria, A
  • Therapy-related peripheral neuropathy in multiple myeloma patients
    Morawska, M; Grzasko, N; Kostyra, M; Wojciechowicz, J; Hus, M
  • Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring
    Mileshkin, L; Stark, R; Day, B; Seymour, JF; Zeldis, JB; Prince, HM
  • Thalidomide-induced neuropathy
    Chaudhry, V; Cornblath, DR; Corse, A; Freimer, M; Simmons-O'Brien, E; Vogelsang, G
  • Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy
    Chaudhry, V; Cornblath, DR; Polydefkis, M; Ferguson, A; Borrello, I
  • Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features
    Isoardo, G; Bergui, M; Durelli, L; Barbero, P; Boccadoro, M; Bertola, A
  • Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
    Richardson, PG; Briemberg, H; Jagannath, S; Wen, PY; Barlogie, B; Berenson, J
  • Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma
    Tosi, P; Zamagni, E; Cellini, C; Plasmati, R; Cangini, D; Tacchetti, P
  • Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study
    Cavaletti, G; Beronio, A; Reni, L; Ghiglione, E; Schenone, A; Briani, C
  • “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
    Katodritou, E; Vadikolia, C; Lalagianni, C; Kotsopoulou, M; Papageorgiou, G; Kyrtsonis, MC
  • A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
    Glasmacher, A; Hahn, C; Hoffmann, F; Naumann, R; Goldschmidt, H; von Lilienfeld-Toal, M
  • Neuropathy in multiple myeloma treated with thalidomide: a prospective study
    Plasmati, R; Pastorelli, F; Cavo, M; Petracci, E; Zamagni, E; Tosi, P
  • Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, M; Spencer, A; Attal, M; Prince, HM; Harousseau, J-L; Dmoszynska, A
  • Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study
    Briani, C; Torre, CD; Campagnolo, M; Lucchetta, M; Berno, T; Candiotto, L
  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
    Miguel, JS; Weisel, K; Moreau, P; Lacy, M; Song, K; Delforge, M
  • Thalidomide and its analogues in the treatment of multiple myeloma
    Latif, T; Chauhan, N; Khan, R; Moran, A; Usmani, SZ
  • Survival gains in multiple myeloma from 2003 to 2014
    Fonseca, R; Jena, AB; Peneva, D; Clancy, Z
  • Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Barlogie, B; Tricot, G; Anaissie, E; Shaughnessy, J; Rasmussen, E; van Rhee, F
  • Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study
    Fullerton, PM; O'Sullivan, DJ
  • Polyneuropathy after neurosedyn (thalidomide) and its prognosis
    Hafström, T
  • Thalidomide induced peripheral neuropathy in multiple myeloma patients
    Banach, M; Jurczyszyn, A; Skotnicki, A
  • Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma
    Luczkowska, K; Litwinska, Z; Paczkowska, E; Machalinski, B
  • Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells
    Tamilarasan, KP; Kolluru, GK; Rajaram, M; Indhumathy, M; Saranya, R; Chatterjee, S
  • Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity
    Keifer, JA; Guttridge, DC; Ashburner, BP; Baldwin, AS
  • Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF
    Kirchmair, R; Tietz, AB; Panagiotou, E; Walter, DH; Silver, M; Yoon, YS
  • US Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma
    Herndon, TM; Deisseroth, A; Kaminskas, E; Kane, RC; Koti, KM; Rothmann, MD
  • Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy
    Kane, RC; Bross, PF; Farrell, AT; Pazdur, R
  • Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
    Pantani, L; Zamagni, E; Zannetti, BA; Pezzi, A; Tacchetti, P; Brioli, A
  • Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
    Argyriou, AA; Iconomou, G; Kalofonos, HP
  • A phase 2 study of bortezomib in relapsed, refractory myeloma
    Richardson, PG; Barlogie, B; Berenson, J; Singhal, S; Jagannath, S; Irwin, D
  • Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
    Kropff, M; Bisping, G; Schuck, E; Liebisch, P; Lang, N; Hentrich, M
  • Bortezomib for the treatment of mantle cell lymphoma
    Kane, RC; Dagher, R; Farrell, A; Ko, CW; Sridhara, R; Justice, R
  • Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib
    Martin, TG
  • Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
    Kumar, SK; Berdeja, JG; Niesvizky, R; Lonial, S; Laubach, JP; Hamadani, M
  • Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
    Stewart, AK; Rajkumar, SV; Dimopoulos, MA; Masszi, T; Špička, I; Oriol, A
  • Management of multiple myeloma in the relapsed/refractory patient
    Sonneveld, P
  • Update on the optimal use of bortezomib in the treatment of multiple myeloma
    Mohan, M; Matin, A; Davies, FE
  • Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines
    Landowski, TH; Megli, CJ; Nullmeyer, KD; Lynch, RM; Dorr, RT
  • Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat
    Cavaletti, G; Gilardini, A; Canta, A; Rigamonti, L; Rodriguez-Menendez, V; Ceresa, C
  • Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats
    Meregalli, C; Canta, A; Carozzi, VA; Chiorazzi, A; Oggioni, N; Gilardini, A
  • Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy
    Zheng, H; Xiao, WH; Bennett, GJ
  • Protection of bortezomib-induced neurotoxicity by antioxidants
    Iijima, Y; Bandow, K; Amano, S; Sano, M; Hino, S; Kaneko, T
  • Inhibition of the neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model
    Alé, A; Bruna, J; Calls, A; Karamita, M; Haralambous, S; Probert, L
  • Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α
    Zhao, W; Wang, W; Li, X; Liu, Y; Gao, H; Jiang, Y
  • GATA3-dependent epigenetic upregulation of CCL21 is involved in the development of neuropathic pain induced by bortezomib
    Zheng, Y; Sun, Y; Yang, Y; Zhang, S; Xu, T; Xin, W
  • Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity
    Park, SB; Alberti, P; Kolb, NA; Gewandter, JS; Schenone, A; Argyriou, AA
  • Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools
    Cavaletti, G; Frigeni, B; Lanzani, F; Mattavelli, L; Susani, E; Alberti, P
  • Prospective evaluation of health care provider and patient assessments in chemotherapy induced peripheral neurotoxicity
    Alberti, P; Bernasconi, DP; Cornblath, DR; Jose Merkies, IS; Park, SB; Velasco, R
  • Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer
    Kandula, T; Farrar, MA; Kiernan, MC; Krishnan, AV; Goldstein, D; Horvath, L
  • Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity
    Park, SB; Goldstein, D; Lin, CS; Krishnan, AV; Friedlander, ML; Kiernan, MC
  • Oxaliplatin and axonal Na+ channel function in vivo
    Krishnan, AV; Goldstein, D; Friedlander, M; Kiernan, MC
  • The pathophysiology of oxaliplatin-induced neurotoxicity
    Kiernan, MC; Krishnan, AV
  • A review on oxaliplatin-induced peripheral nerve damage
    Argyriou, AA; Polychronopoulos, P; Iconomou, G; Chroni, E; Kalofonos, HP
  • Peripheral nerve damage associated with administration of taxanes in patients with cancer
    Argyriou, AA; Koltzenburg, M; Polychronopoulos, P; Papapetropoulos, S; Kalofonos, HP
  • Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy
    Park, SB; Lin, CSY; Krishnan, AV; Goldstein, D; Friedlander, ML; Kiernan, MC
  • Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity
    Park, SB; Lin, CSY; Krishnan, AV; Goldstein, D; Friedlander, ML; Kiernan, MC
  • Early changes in tests of peripheral nerve function during oxaliplatin treatment and their correlation with chemotherapy-induced polyneuropathy symptoms and signs
    Krøigård, T; Svendsen, TK; Wirenfeldt, M; Schrøder, HD; Qvortrup, C; Pfeiffer, P
  • 6 Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy
    Murray, JE; Pickering, HR; Lin, CSY; Goldstein, D; Friedlander, ML; Kiernan, MC
  • Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation
    Osmani, K; Vignes, S; Aissi, M; Wade, F; Milani, P; Lévy, BI
  • Clinical and electrophysiological studies in vincristine induced neuropathy
    Pal, PK
  • Taxane-induced peripheral neuropathy: differences in patient report and objective assessment
    Timmins, HC; Li, T; Kiernan, MC; Baron-Hay, S; Marx, G; Boyle, F
  • Electrophysiological and phenotypic profiles of taxane-induced neuropathy
    Timmins, HC; Li, T; Huynh, W; Kiernan, MC; Baron-Hay, S; Boyle, F
  • Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device
    Matsuoka, A; Mitsuma, A; Maeda, O; Kajiyama, H; Kiyoi, H; Kodera, Y
  • Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy
    Kocer, B; Sucak, G; Kuruoglu, R; Aki, Z; Haznedar, R; Erdogmus, NI
  • Thermal sensibility changes during ischemie nerve block
    Fruhstorfer, H
  • Roles of capsaicin-insensitive nociceptors in cutaneous pain and secondary hyperalgesia
    Magerl, W; Fuchs, PN; Meyer, RA; Treede, R-D
  • Secondary hyperalgesia to punctate mechanical stimuli: central sensitization to A-fibre nociceptor input
    Ziegler, EA; Magerl, W; Meyer, RA; Treede, R-D
  • Peripheral neuropathy research registry: a prospective cohort
    Thomas, S; Ajroud-Driss, S; Dimachkie, MM; Gibbons, C; Freeman, R; Simpson, DM
  • Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies
    Krøigård, T; Schrøder, HD; Qvortrup, C; Eckhoff, L; Pfeiffer, P; Gaist, D
  • Reliability and accuracy of quantitative sensory testing for oxaliplatin-induced neurotoxicity
    Velasco, R; Videla, S; Villoria, J; Ortiz, E; Navarro, X; Bruna, J
  • Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing
    Zhi, WI; Chen, P; Kwon, A; Chen, C; Harte, SE; Piulson, L
  • Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain
    Dougherty, PM; Cata, JP; Burton, AW; Vu, K; Weng, HR
  • Quantitative sensory findings in patients with bortezomib-induced pain
    Cata, JP; Weng, HR; Burton, AW; Villareal, H; Giralt, S; Dougherty, PM
  • EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy
    Lauria, G; Cornblath, DR; Johansson, O; McArthur, JC; Mellgren, SI; Nolano, M
  • Skin biopsy: a new tool for diagnosing peripheral neuropathy
    Lauria, G; Lombardi, R
  • Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy
    Collongues, N; Samama, B; Schmidt-Mutter, C; Chamard-Witkowski, L; Debouverie, M; Chanson, J-B
  • Longitudinal assessment of oxaliplatininduced neuropathy
    Burakgazi, AZ; Messersmith, W; Vaidya, D; Hauer, P; Hoke, A; Polydefkis, M
  • Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain
    Bechakra, M; Nieuwenhoff, MD; van Rosmalen, J; Groeneveld, GJ; Scheltens-de Boer, M; Sonneveld, P
  • Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy
    Alam, U; Jeziorska, M; Petropoulos, IN; Asghar, O; Fadavi, H; Ponirakis, G
  • Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density
    Chen, X; Graham, J; Dabbah, MA; Petropoulos, IN; Ponirakis, G; Asghar, O
  • Use of corneal confocal microscopy to evaluate small nerve fibers in patients with human immunodeficiency virus
    Kemp, HI; Petropoulos, IN; Rice, ASC; Vollert, J; Maier, C; Strum, D
  • Corneal confocal microscopy detects small fibre neuropathy in patients with upper gastrointestinal cancer and nerve regeneration in chemotherapy induced peripheral neuropathy
    Ferdousi, M; Azmi, S; Petropoulos, IN; Fadavi, H; Ponirakis, G; Marshall, A
  • Surrogate markers of small fiber damage in human diabetic neuropathy
    Quattrini, C; Tavakoli, M; Jeziorska, M; Kallinikos, P; Tesfaye, S; Finnigan, J
  • Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy
    Stettner, M; Hinrichs, L; Guthoff, R; Bairov, S; Petropoulos, IN; Warnke, C
  • Burden of chemotherapy-induced neuropathy—a cross-sectional study
    Kautio, A-L; Haanpaa, M; Kautiainen, H; Kalso, E; Saarto, T
  • Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study
    Azmi, S; Ferdousi, M; Alam, U; Petropoulos, IN; Ponirakis, G; Marshall, A
  • Reduction of skin innervation is associated with a severe fibromyalgia phenotype
    Evdokimov, D; Frank, J; Klitsch, A; Unterecker, S; Warrings, B; Serra, J
  • Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study
    Perkins, BA; Lovblom, LE; Bril, V; Scarr, D; Ostrovski, I; Orszag, A
  • Rapid corneal nerve fiber loss: a marker of diabetic neuropathy onset and progression
    Lewis, EJH; Lovblom, LE; Ferdousi, M; Halpern, EM; Jeziorska, M; Pacaud, D
  • Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings
    Argyriou, AA; Park, SB; Islam, B; Tamburin, S; Velasco, R; Alberti, P
  • Corneal confocal microscopy in patients with chemotherapy-induced neuropathy
    Campagnolo, M; Lazzarini, D; Cacciavillani, M; Fregona, I; Bergamo, F; Lonardi, S
  • Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study
    Cocito, F; Ricciardelli, G; Mangiacavalli, S; Pompa, A; Pochintesta, L; Ferretti, V
  • Oxaliplatin- and docetaxel-induced polyneuropathy: clinical and neurophysiological characteristics
    Bennedsgaard, K; Ventzel, L; Andersen, NT; Themistocleous, AC; Bennett, DL; Jensen, TS
  • The utility of corneal nerve fractal dimension analysis in peripheral neuropathies of different etiology
    Petropoulos, IN; Al-Mohammedi, A; Chen, X; Ferdousi, M; Ponirakis, G; Kemp, H
  • A cross-sectional study of sub-basal corneal nerve reduction following neurotoxic chemotherapy
    Chiang, JCB; Goldstein, D; Trinh, T; Au, K; Mizrahi, D; Muhlmann, M
  • Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review
    Bennett, MI; Rayment, C; Hjermstad, M; Aass, N; Caraceni, A; Kaasa, S
  • Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients
    Oh, SY; Shin, SW; Koh, S-J; Bae, SB; Chang, H; Kim, JH
  • Burden of chemotherapy-induced neuropathy—a cross-sectional study
    Kautio, AL; Haanpää, M; Kautiainen, H; Kalso, E; Saarto, T
  • Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry
    Ezendam, NP; Pijlman, B; Bhugwandass, C; Pruijt, JF; Mols, F; Vos, MC
  • Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study
    Gewandter, JS; Fan, L; Magnuson, A; Mustian, K; Peppone, L; Heckler, C
  • Neurotoxicity of taxanes: symptoms and quality of life assessment
    Kuroi, K; Shimozuma, K
  • Chemotherapy-Induced Neuropathy in Cancer Survivors
    Miaskowski, C; Mastick, J; Paul, SM; Topp, K; Smoot, B; Abrams, G
  • Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry
    Mols, F; Beijers, T; Lemmens, V; van den Hurk, CJ; Vreugdenhil, G; van de Poll-Franse, LV
  • Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review
    Mols, F; Beijers, T; Vreugdenhil, G; van de Poll-Franse, L
  • Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment
    Zanville, NR; Nudelman, KN; Smith, DJ; Von Ah, D; McDonald, BC; Champion, VL
  • Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis
    Song, X; Wilson, KL; Kagan, J; Panjabi, S
  • Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer
    Pike, CT; Birnbaum, HG; Muehlenbein, CE; Pohl, GM; Natale, RB
  • Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
    Finnerup, NB; Attal, N; Haroutounian, S; McNicol, E; Baron, R; Dworkin, RH
  • Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update
    Loprinzi, CL; Lacchetti, C; Bleeker, J; Cavaletti, G; Chauhan, C; Hertz, DL
  • Interventions for preventing neuropathy caused by cisplatin and related compounds
    Albers, JW; Chaudhry, V; Cavaletti, G; Donehower, RC
  • Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy
    Hershman, DL; Unger, JM; Crew, KD; Minasian, LM; Awad, D; Moinpour, CM
  • Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations
    Gewandter, JS; Brell, J; Cavaletti, G; Dougherty, PM; Evans, S; Howie, L
  • Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial
    Guo, Y; Jones, D; Palmer, JL; Forman, A; Dakhil, SR; Velasco, MR
  • Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study
    Desideri, I; Francolini, G; Becherini, C; Terziani, F; Delli Paoli, C; Olmetto, E
  • Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial
    Howells, LM; Iwuji, COO; Irving, GRB; Barber, S; Walter, H; Sidat, Z
  • Prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and α-lipoic acid in patients with multiple myeloma: preliminary data
    Maschio, M; Zarabla, A; Maialetti, A; Marchesi, F; Giannarelli, D; Gumenyuk, S
  • Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy
    Pace, A; Savarese, A; Picardo, M; Maresca, V; Pacetti, U; Del Monte, G
  • Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?
    Pace, A; Nisticò, C; Cuppone, F; Bria, E; Galiè, E; Graziano, G
  • The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial
    Kottschade, LA; Sloan, JA; Mazurczak, MA; Johnson, DB; Murphy, BP; Rowland, KM
  • Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial
    Argyriou, AA; Chroni, E; Koutras, A; Ellul, J; Papapetropoulos, S; Katsoulas, G
  • Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial
    Cascinu, S; Catalano, V; Cordella, L; Labianca, R; Giordani, P; Baldelli, AM
  • Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial
    Cascinu, S; Cordella, L; Del Ferro, E; Fronzoni, M; Catalano, G
  • North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study
    Leal, AD; Qin, R; Atherton, PJ; Haluska, P; Behrens, RJ; Tiber, CH
  • Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients
    Wang, WS; Lin, JK; Lin, TC; Chen, WS; Jiang, JK; Wang, HS
  • Reduction of paclitaxel-induced peripheral neuropathy with glutamine
    Vahdat, L; Papadopoulos, K; Lange, D; Leuin, S; Kaufman, E; Donovan, D
  • Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study
    Stubblefield, MD; Vahdat, LT; Balmaceda, CM; Troxel, AB; Hesdorffer, CS; Gooch, CL
  • Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer
    Leong, SS; Tan, EH; Fong, KW; Wilder-Smith, E; Ong, YK; Tai, BC
  • Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group
    Hilpert, F; Stähle, A; Tomé, O; Burges, A; Rossner, D; Späthe, K
  • Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma
    Gurney, JG; Bass, JK; Onar-Thomas, A; Huang, J; Chintagumpala, M; Bouffet, E
  • Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities
    Gandara, DR; Nahhas, WA; Adelson, MD; Lichtman, SM; Podczaski, ES; Yanovich, S
  • The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients
    Knijn, N; Tol, J; Koopman, M; Werter, MJ; Imholz, AL; Valster, FA
  • Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer
    Gamelin, L; Boisdron-Celle, M; Delva, R; Guérin-Meyer, V; Ifrah, N; Morel, A
  • Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: a meta-analysis
    Ao, R; Wang, YH; Li, RW; Wang, ZR
  • Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study
    Loprinzi, CL; Qin, R; Dakhil, SR; Fehrenbacher, L; Stella, PJ; Atherton, PJ
  • Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance)
    Loprinzi, CL; Qin, R; Dakhil, SR; Fehrenbacher, L; Flynn, KA; Atherton, P
  • Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients
    Han, CH; Khwaounjoo, P; Kilfoyle, DH; Hill, A; McKeage, MJ
  • Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review
    Flatters, SJL; Dougherty, PM; Colvin, LA
  • Chemotherapy-induced peripheral neuropathy clinical trials: review and recommendations
    Gewandter, JS; Freeman, R; Kitt, RA; Cavaletti, G; Gauthier, LR; McDermott, MP
  • Treatment of chemotherapy-induced peripheral neuropathy in integrative oncology: a survey of acupuncture and oriental medicine practitioners
    Lu, Z; Moody, J; Marx, BL; Hammerstrom, T
  • A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy
    Li, K; Giustini, D; Seely, D
  • Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
    Han, X; Wang, L; Shi, H; Zheng, G; He, J; Wu, W
  • Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture
    Rostock, M; Jaroslawski, K; Guethlin, C; Ludtke, R; Schröder, S; Bartsch, HH
  • Efficacy and safety of acupuncture against chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
    Jin, Y; Wang, Y; Zhang, J; Xiao, X; Zhang, Q
  • Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study
    Hsieh, YL; Chou, LW; Hong, SF; Chang, FC; Tseng, SW; Huang, CC
  • Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
    Garcia, MK; Cohen, L; Guo, Y; Zhou, Y; You, B; Chiang, J
  • Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
    Kleckner, IR; Kamen, C; Gewandter, JS; Mohile, NA; Heckler, CE; Culakova, E
  • The effects of exercise on chemotherapy-induced peripheral neuropathy symptoms in cancer patients: a systematic review and meta-analysis
    Lin, WL; Wang, RH; Chou, FH; Feng, IJ; Fang, CJ; Wang, HH
  • A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP Study of 462 cancer survivors
    Gewandter, JS; Mohile, SG; Heckler, CE; Ryan, JL; Kirshner, JJ; Flynn, PJ
  • High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies
    Rossignol, J; Cozzi, B; Liebaert, F; Hatton, S; Viallard, ML; Hermine, O
  • Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons
    Anand, U; Otto, WR; Anand, P
  • High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience
    Filipczak-Bryniarska, I; Krzyzewski, RM; Kucharz, J; Michalowska-Kaczmarczyk, A; Kleja, J; Woron, J
  • Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification
    Anand, P; Elsafa, E; Privitera, R; Naidoo, K; Yiangou, Y; Donatien, P
  • Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea
    Kim, B-S; Jin, J-Y; Kwon, JH; Woo, IS; Ko, YH; Park, S-Y
  • Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma
    Cartoni, C; Brunetti, GA; Federico, V; Efficace, F; Grammatico, S; Tendas, A
  • Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States
    Bykov, K; Bateman, BT; Franklin, JM; Vine, SM; Patorno, E
  • A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study
    Mishra, S; Bhatnagar, S; Goyal, GN; Rana, SP; Upadhya, SP
  • Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study
    Tsavaris, N; Kopterides, P; Kosmas, C; Efthymiou, A; Skopelitis, H; Dimitrakopoulos, A
  • Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy
    Magnowska, M; Izycka, N; Kapola-Czyz, J; Romala, A; Lorek, J; Spaczynski, M
  • Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)
    Rao, RD; Loprinzi, CL; Michalak, JC; Sloan, JA; Novotny, P; Soori, GS
  • Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized Double-Blind Trial
    de Andrade, DC; Jacobsen Teixeira, M; Galhardoni, R; Ferreira, KSL; Braz Mileno, P; Scisci, N
  • Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy
    Hammack, JE; Michalak, JC; Loprinzi, CL; Sloan, JA; Novotny, PJ; Soori, GS
  • Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms
    Kautio, A-L; Haanpää, M; Saarto, T; Kalso, E
  • Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms
    Kautio, AL; Haanpää, M; Leminen, A; Kalso, E; Kautiainen, H; Saarto, T
  • A greater role for the norepinephrine transporter than the serotonin transporter in murine nociception
    Hall, FS; Schwarzbaum, JM; Perona, MTG; Templin, JS; Caron, MG; Lesch, KP
  • Duloxetine: a review of its pharmacology and use in chronic pain management
    Bellingham, GA; Peng, PW
  • Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial
    Smith, EM; Pang, H; Cirrincione, C; Fleishman, S; Paskett, ED; Ahles, T
  • Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy. A randomized clinical trial
    Smith, EML; Pang, H; Cirrincione, C; Fleishman, S; Paskett, ED; Ahles, T
  • Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study
    Yang, YH; Lin, JK; Chen, WS; Lin, TC; Yang, SH; Jiang, JK
  • Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial
    Hirayama, Y; Ishitani, K; Sato, Y; Iyama, S; Takada, K; Murase, K
  • Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial—CALGB/alliance 170601
    Smith, EM; Pang, H; Ye, C; Cirrincione, C; Fleishman, S; Paskett, ED
  • Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy
    Farshchian, N; Alavi, A; Heydarheydari, S; Moradian, N
  • Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial
    Durand, JP; Deplanque, G; Montheil, V; Gornet, JM; Scotte, F; Mir, O
  • Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case–control study
    Kus, T; Aktas, G; Alpak, G; Kalender, ME; Sevinc, A; Kul, S
  • MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy
    Zimmerman, C; Atherton, PJ; Pachman, D; Seisler, D; Wagner-Johnston, N; Dakhil, S
  • Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer
    Leonard, GD; Wright, MA; Quinn, MG; Fioravanti, S; Harold, N; Schuler, B
  • Predicting acute and persistent neuropathy associated with oxaliplatin
    Alejandro, LM; Behrendt, CE; Chen, K; Openshaw, H; Shibata, S
  • Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
    Rothenberg, ML; Oza, AM; Bigelow, RH; Berlin, JD; Marshall, JL; Ramanathan, RK
  • Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
    Yamada, Y; Higuchi, K; Nishikawa, K; Gotoh, M; Fuse, N; Sugimoto, N
  • Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer
    Bando, H; Yamada, Y; Tanabe, S; Nishikawa, K; Gotoh, M; Sugimoto, N
  • Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
    Lonardi, S; Sobrero, A; Rosati, G; Di Bartolomeo, M; Ronzoni, M; Aprile, G
  • Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
    Al-Batran, SE; Hartmann, JT; Probst, S; Schmalenberg, H; Hollerbach, S; Hofheinz, R
  • Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    Cassidy, J; Clarke, S; Díaz-Rubio, E; Scheithauer, W; Figer, A; Wong, R
  • OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study
    Tournigand, C; Cervantes, A; Figer, A; Lledo, G; Flesch, M; Buyse, M
  • Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    André, T; Boni, C; Mounedji-Boudiaf, L; Navarro, M; Tabernero, J; Hickish, T
  • A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration
    Beijers, AJ; Mols, F; Vreugdenhil, G
  • Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for Stage II and III colon cancer: NSABP C-07
    Land, SR; Kopec, JA; Cecchini, RS; Ganz, PA; Wieand, HS; Colangelo, LH
  • FDA drug approval summaries: oxaliplatin
    Ibrahim, A; Hirschfeld, S; Cohen, MH; Griebel, DJ; Williams, GA; Pazdur, R
  • Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies
    Argyriou, AA; Polychronopoulos, P; Iconomou, G; Koutras, A; Kalofonos, HP; Chroni, E
  • Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis
    Peng, L; Bu, Z; Ye, X; Zhou, Y; Zhao, Q
  • Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial
    Socinski, MA; Bondarenko, I; Karaseva, NA; Makhson, AM; Vynnychenko, I; Okamoto, I
  • A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101
    Baldwin, RM; Owzar, K; Zembutsu, H; Chhibber, A; Kubo, M; Jiang, C
  • The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity: a case–control study
    Dorling, L; Kar, S; Michailidou, K; Hiller, L; Vallier, AL; Ingle, S
  • Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
    Scagliotti, G; Novello, S; von Pawel, J; Reck, M; Pereira, JR; Thomas, M
  • Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    Scagliotti, GV; De Marinis, F; Rinaldi, M; Crinò, L; Gridelli, C; Ricci, S
  • A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer
    Gao, G; Chu, H; Zhao, L; Gui, T; Xu, Q; Shi, J
  • Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia
    Ramchandren, S; Leonard, M; Mody, RJ; Donohue, JE; Moyer, J; Hutchinson, R
  • Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia
    Lavoie Smith, EM; Li, L; Chiang, C; Thomas, K; Hutchinson, RJ; Wells, EM
  • Thalidomide and dexamethasone combination for refractory multiple myeloma
    Dimopoulos, MA; Zervas, K; Kouvatseas, G; Galani, E; Grigoraki, V; Kiamouris, C
  • A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
    Prince, HM; Mileshkin, L; Roberts, A; Ganju, V; Underhill, C; Catalano, J
  • A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
    von Lilienfeld-Toal, M; Hahn-Ast, C; Furkert, K; Hoffmann, F; Naumann, R; Bargou, R
  • An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
    Prince, HM; Schenkel, B; Mileshkin, L
  • The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma
    Grover, JK; Uppal, G; Raina, V
  • Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Facon, T; Mary, JY; Hulin, C; Benboubker, L; Attal, M; Pegourie, B
  • A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    Richardson, PG; Blood, E; Mitsiades, CS; Jagannath, S; Zeldenrust, SR; Alsina, M
  • Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib
    Peng, L; Ye, X; Zhou, Y; Zhang, J; Zhao, Q
  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Richardson, PG; Sonneveld, P; Schuster, MW; Irwin, D; Stadtmauer, EA; Facon, T
  • Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
    Richardson, PG; Sonneveld, P; Schuster, MW; Stadtmauer, EA; Facon, T; Harousseau, J-L
  • Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses
    Aguiar, PM; de Mendonça, LT; Colleoni, GWB; Storpirtis, S
  • Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin
    van der Hoop, RG; van der Burg, ME; ten Bokkel Huinink, WW; van Houwelingen, C; Neijt, JP
  • The physical consequences of chemotherapy-induced peripheral neuropathy
    Tofthagen, CS; Cheville, AL; Loprinzi, CL
  • Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial
    Ruddy, KJ; Le-Rademacher, J; Lacouture, ME; Wilkinson, M; Onitilo, AA; Vander Woude, AC
  • Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1
    Reeves, BN; Dakhil, SR; Sloan, JA; Wolf, SL; Burger, KN; Kamal, A
  • Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy
    Molassiotis, A; Cheng, HL; Leung, KT; Li, YC; Wong, KH; Au, JSK
  • Chemotherapy-induced neuropathy:a comprehensive survey
    Miltenburg, NC; Boogerd, W
  • Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1
    Loprinzi, CL; Reeves, BN; Dakhil, SR; Sloan, JA; Wolf, SL; Burger, KN
  • Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma
    Liu, H; Xu, R; Huang, H
  • Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment
    Kang, L; Tian, Y; Xu, S; Chen, H
  • Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline
    Hershman, DL; Lacchetti, C; Dworkin, RH; Lavoie Smith, EM; Bleeker, J; Cavaletti, G
  • Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer
    Glendenning, JL; Barbachano, Y; Norman, AR; Dearnaley, DP; Horwich, A; Huddart, RA
  • Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer
    Eckhoff, L; Feddersen, S; Knoop, AS; Ewertz, M; Bergmann, TK
  • Management of oxaliplatin-induced peripheral sensory neuropathy
    Cavaletti, G; Marmiroli, P
  • Chemotherapy-induced peripheral neurotoxicity
    Cavaletti, G; Marmiroli, P
  • Observational study of prevalence of long-term raynaud-like phenomena and neurological side effects in testicular cancer survivors
    Brydøy, M; Oldenburg, J; Klepp, O; Bremnes, RM; Wist, EA; Wentzel-Larsen, T
  • Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
    Argyriou, AA; Polychronopoulos, P; Koutras, A; Iconomou, G; Gourzis, P; Assimakopoulos, K
  • Bortezomib-induced peripheral neurotoxicity: an update
    Argyriou, AA; Cavaletti, G; Bruna, J; Kyritsis, AP; Kalofonos, HP
  • Thalidomide-induced orofacial neuropathy
    Anyanwu, CO; Stewart, CL; Werth, VP
  • Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724)
    Albany, C; Dockter, T; Wolfe, E; Le-Rademacher, J; Wagner-Johnston, N; Einhorn, L
  • DrugBank 50: a major update to the DrugBank database for 2018
    Wishart, DS; Feunang, YD; Guo, AC; Lo, EJ; Marcu, A; Grant, JR
  • Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid
    Gedlicka, C; Scheithauer, W; Schüll, B; Kornek, GV
  • Amelioration of docetaxel/cisplatin induced polyneuropathy by {alpha}-lipoic acid
    Gedlicka, C; Kornek, GV; Schmid, K; Scheithauer, W
  • The effect of docosahexaenoic acid and α-lipoic acid as prevention of bortezomib-related neurotoxicity in patients with multiple myeloma
    Maschio, M; Zarabla, A; Maialetti, A; Marchesi, F; Giannarelli, D; Gumenyuk, S
  • A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer
    Roberts, JA; Jenison, EL; Kim, K; Clarke-Pearson, D; Langleben, A
  • Lack of neuroprotection by an ACTH (4–9) analogue. a randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma
    Koeppen, S; Verstappen, CC; Körte, R; Scheulen, ME; Strumberg, D; Postma, TJ
  • Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity
    Milla, P; Airoldi, M; Weber, G; Drescher, A; Jaehde, U; Cattel, L
  • Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: an assessor-blinded randomized controlled trial
    Izgu, N; Metin, ZG; Karadas, C; Ozdemir, L; Cetin, N; Demirci, U
  • Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer
    Greenlee, H; Crew, KD; Capodice, J; Awad, D; Buono, D; Shi, Z
  • Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx(®)): a placebo-controlled randomised phase II study (PLIANT)
    Glimelius, B; Manojlovic, N; Pfeiffer, P; Mosidze, B; Kurteva, G; Karlberg, M
  • Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy
    Argyriou, AA; Chroni, E; Polychronopoulos, P; Iconomou, G; Koutras, A; Makatsoris, T
  • Acute oxaliplatin-induced peripheral nerve hyperexcitability
    Wilson, RH; Lehky, T; Thomas, RR; Quinn, MG; Floeter, MK; Grem, JL
  • Effect of aromatherapy massage on chemotherapy-induced peripheral neuropathic pain and fatigue in patients receiving oxaliplatin: an open label quasi-randomized controlled pilot study
    Izgu, N; Ozdemir, L; Bugdayci, BF
  • A randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy
    Molassiotis, A; Suen, LKP; Cheng, HL; Mok, TSK; Lee, SCY; Wang, CH
  • Intravenous lidocaine old-school drug, new purpose—reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy
    van den Heuvel, SAS; van der Wal, SEI; Smedes, LA; Radema, SA; van Alfen, N; Vissers, KCP
  • Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3
    Rao, RD; Loprinzi, CL; Flynn, PJ; Nashawaty, M; Sloan, JA; Novotny, P
  • A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain
    Lynch, ME; Cesar-Rittenberg, P; Hohmann, AG
  • A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
    Barton, DL; Wos, EJ; Qin, R; Mattar, BI; Green, NB; Lanier, KS
  • Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist
    Fallon, MT; Storey, DJ; Krishan, A; Weir, CJ; Mitchell, R; Fleetwood-Walker, SM
  • Management of cancer pain: ESMO Clinical Practice Guidelines
    Ripamonti, CI; Santini, D; Maranzano, E; Berti, M; Roila, F
  • Brief review: chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions
    Massey, RL; Kim, HK; Abdi, S
  • Management of peripheral neuropathy induced by chemotherapy
    Fradkin, M; Batash, R; Elmaleh, S; Debi, R; Schaffer, P; Schaffer, M
  • The National Cancer Institute Clinical Trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy
    Dorsey, SG; Kleckner, IR; Barton, D; Mustian, K; O'Mara, A; St Germain, D
  • EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
    Attal, N; Cruccu, G; Baron, R; Haanpaa, M; Hansson, P; Jensen, TS
  • Usefulness of duloxetine for paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients
    Otake, A; Yoshino, K; Ueda, Y; Sawada, K; Mabuchi, S; Kimura, T
  • Venlafaxine for treatment of chemotherapy-induced neuropathic pain
    Özdoǧan, M; Samur, M; Bozcuk, HŞ; Çoban, E; Savaş, B; Aydin, H
  • Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy
    Durand, JP; Alexandre, J; Guillevin, L; Goldwasser, F
  • Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy
    Saif, MW; Syrigos, K; Kaley, K; Isufi, I